Claims for Patent: 7,582,618

Summary for Patent: 7,582,618

Title:	2\'-C-methyl-3\'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
Abstract:	The 3\'-L-valine ester of .beta.-D-2\'-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.
Inventor(s):	Sommadossi; Jean-Pierre (Cambridge, MA), LaColla; Paolo (Capoterra, IT), Gosselin; Gilles (Montpellier, FR)
Assignee:	Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR)
Application Number:	11/516,928
Patent Claims:	1. A method of treating a host infected with a Flaviviridae virus, comprising administering to the host an effective amount of a compound having the structure of the formula: ##STR00006## or a pharmaceutically acceptable salt or prodrug thereof optionally in a pharmaceutically acceptable carrier. 2. The method according to claim 1, wherein the pharmaceutically acceptable salt is a hydrochloride salt. 3. The method according to claim 1, wherein the pharmaceutically acceptable salt is a dihydrochloride salt. 4. The method according to claim 1, further comprising administering the compound in a pharmaceutically acceptable carrier, diluent or excipient. 5. The method according to claim 1, wherein the compound is administered in combination or alternation with a second anti-viral agent. 6. The method according to claim 5, wherein the second antiviral agent is selected from the group consisting of an interferon, ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, thiazolidine derivative, thiazolidine, benzanilide, phenan-threnequinone, a helicase inhibitor, a polymerase inhibitor, a nucleoside analogue, gliotoxin, cerulenin, antisense phosphorothioate oligodeoxynucleotides, an inhibitor of IRES-dependent translation, and a ribozyme. 7. The method according to claim 5, wherein the second antiviral agent is an interferon. 8. The method according to claim 7, wherein the second agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon gamma-1b. 9. The method of claim 8, wherein the second antiviral agent is interferon alpha 2. 10. The method of claim 1, wherein the host is a human. 11. The method of claim 1, wherein the compound is in the form of a dosage unit. 12. The method of claim 11, wherein the dosage unit contains 70 to 1400 mg of the compound. 13. The method of claim 11, wherein the dosage unit is a tablet or capsule. 14. The method of any one of claims 1-3, wherein the pharmaceutically acceptable carrier is suitable for oral or intravenous delivery. 15. The method of any one of claims 1-3, wherein the compound is administered in substantially pure form. 16. The method of any one of claims 1-3, wherein the compound is at least 90% by weight of the .beta.-D-isomer. 17. The method of any one of claims 1-3, wherein the compound is at least 95% by weight of the .beta.-D-isomer. 18. The method of any one of claims 1-3, wherein the virus is hepatitis C. 19. A method for treating a host infected with an RNA-dependant RNA polymerase virus, comprising administering an effective amount of the compound of the formula: ##STR00007## or its mono or dihydrochloride in pharmaceutically acceptable carrier, wherein the 5'-hydroxyl group is replaced with a 5'-OR, wherein R is hydrogen, phosphate; a stabilized phosphate prodrug; acyl; an amino acid; a carbohydrate; a peptide; or other pharmaceutically acceptable leaving group which when administered in viva provides a compound wherein R is independently H or phosphate. 20. The method of claim 19 wherein the virus is a F/aviviridae virus. 21. The method of claim 19 or 20 wherein the Flaviviridae virus is hepatitis C. 22. The method of claim 19 or 20 wherein the host is a human. 23. The method of claim 1, wherein the pharmaceutically acceptable salt is selected from tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, .alpha.-ketoglutarate, and .alpha.-glycerophosphate, formate, fumarate, propionate, glycolate, lactate, pyruvate, oxalate, maleate, salicyate, sulfate, sulfonate, nitrate, hydrobromate, hydrobromide, hydroiodide, and phosphoric acid salts. 24. The method of claim 19, wherein the compound or a pharmaceutically acceptable salt thereof, is administered in combination with a pharmaceutically acceptable carrier. 25. The method of claim 24, wherein the carrier is suitable for oral or intravenous delivery. 26. The method of claim 19, wherein the compound is in the form of a dosage unit. 27. The method of claim 19, wherein the compound is administered in substantially pure form. 28. The method of claim 19, wherein the compound is at least 90% by weight of the .beta.-D-isomer. 29. The method of claim 19, wherein the compound is at least 95% by weight of the .beta.-D-isomer. 30. The method of claim 11 or 26, wherein the dosage unit contains 50 mg to 1000 mg of the compound. 31. The method of claim 11 or 26, wherein the dosage unit contains 100 mg of the compound. 32. The method of claim 11 or 26, wherein the dosage unit contains 200 mg of the compound. 33. The method of claim 11 or 26, wherein the dosage unit contains 400 mg of the compound. 34. The method of claim 11 or 26, wherein the dosage unit contains 800 mg of the compound. 35. The method of claim 11 or 26, wherein the dosage unit contains 1000 mg of the compound. 36. The method of claim 21 wherein the host is a human.

Details for Patent 7,582,618

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2022-06-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2022-06-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2022-06-28
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2022-06-28
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004		2022-06-28